VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ISHL12 2022 | The promise of ADCs in the future treatment of HL

In this video, Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the trials and data surrounding antibody-drug conjugate (ADC) treatment for patients with Hodgkin lymphoma (HL). Dr Collins begins by highlighting the survival benefits associated with brentuximab vedotin in various settings, citing the results of the AETHERA (NCT01100502) and ECHELON-1 (NCT01712490) trials. Following this, Dr Collins sheds light on the toxicities and remission rates associated with the ADC camidanlumab tesirine (Cami). This interview took place at The 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Received honoraria for speaker and advisory work from:
Takeda, Gilead, Roche, Novartis, Incyte, Daiichi Sankyo, Beigene, ADC Therapeutics, Celleron, SecuraBio
Received research funding from:
BMS, MSD, Pfizer, Amgen, Celgene, Beigene

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter